预约演示

Grifols prepares for late-stage plans with plasma-derived medicines in 2024

2024-02-28

临床3期并购临床结果

In an exclusive interview with Pharmaceutical Technology, Grifols declared plans for multiple Phase III readouts in 2024. Credit: Bloomberg via Getty Images

Grifols plans to release Phase Pharmaceutical TechnologyerGrifolsin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific innovations officer Jorg Schüttrumpf.

GrifolsportHow is the Biopharmaceutical industry evolving?decompensated cirrhosis ascites

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

GlobalData’s expansive report examines the business environment and trends that shape the BioCOVID-19 pandemicdustry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Access the report to:

Benchmark the impact of major themes on the Biopharmaceutical industry.

Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.

Evaluate the effects of COVID-19 on the sector.

Download the full reportCOVID-19rstand what to expect and how to align your strategies for success.

Submit

Country Code *

UK (+44)

USA (+1)

Algeria (+213)

Andorra (+376)

Angola (+244)

Anguilla (+1264)

Antigua & Barbuda (+1268)

Argentina (+54)

Armenia (+374)

Aruba (+297)

Australia (+61)

Austria (+43)

Azerbaijan (+994)

Bahamas (+1242)

Bahrain (+973)

Bangladesh (+880)

Barbados (+1246)

Belarus (+375)

Belgium (+32)

Belize (+501)

Benin (+229)

Bermuda (+1441)

Bhutan (+975)

Bolivia (+591)

Bosnia Herzegovina (+387)

Botswana (+267)

Brazil (+55)

Brunei (+673)

Bulgaria (+359)

Burkina Faso (+226)

Burundi (+257)

Cambodia (+855)

Cameroon (+237)

Canada (+1)

Cape Verde Islands (+238)

Cayman Islands (+1345)

Central African Republic (+236)

Chile (+56)

China (+86)

Colombia (+57)

Comoros (+269)

Congo (+242)

Cook Islands (+682)

Costa Rica (+506)

Croatia (+385)

Cuba (+53)

Cyprus North (+90392)

Cyprus South (+357)

Czech Republic (+42)

Denmark (+45)

Djibouti (+253)

Dominica (+1809)

Dominican Republic (+1809)

Ecuador (+593)

Egypt (+20)

El Salvador (+503)

Equatorial Guinea (+240)

Eritrea (+291)

Estonia (+372)

Ethiopia (+251)

Falkland Islands (+500)

Faroe Islands (+298)

Fiji (+679)

Finland (+358)

France (+33)

French Guiana (+594)

French Polynesia (+689)

Gabon (+241)

Gambia (+220)

Georgia (+7880)

Germany (+49)

Ghana (+233)

Gibraltar (+350)

Greece (+30)

Greenland (+299)

Grenada (+1473)

Guadeloupe (+590)

Guam (+671)

Guatemala (+502)

Guinea (+224)

Guinea - Bissau (+245)

Guyana (+592)

Haiti (+509)

Honduras (+504)

Hong Kong (+852)

Hungary (+36)

Iceland (+354)

India (+91)

Indonesia (+62)

Iran (+98)

Iraq (+964)

Ireland (+353)

Israel (+972)

Italy (+39)

Jamaica (+1876)

Japan (+81)

Jordan (+962)

Kazakhstan (+7)

Kenya (+254)

Kiribati (+686)

Korea North (+850)

Korea South (+82)

Kuwait (+965)

Kyrgyzstan (+996)

Laos (+856)

Latvia (+371)

Lebanon (+961)

Lesotho (+266)

Liberia (+231)

Libya (+218)

Liechtenstein (+417)

Lithuania (+370)

Luxembourg (+352)

Macao (+853)

Macedonia (+389)

Madagascar (+261)

Malawi (+265)

Malaysia (+60)

Maldives (+960)

Mali (+223)

Malta (+356)

Marshall Islands (+692)

Martinique (+596)

Mauritania (+222)

Mayotte (+269)

Mexico (+52)

Micronesia (+691)

Moldova (+373)

Monaco (+377)

Mongolia (+976)

Montserrat (+1664)

Morocco (+212)

Mozambique (+258)

Myanmar (+95)

Namibia (+264)

Nauru (+674)

Nepal (+977)

Netherlands (+31)

New Caledonia (+687)

New Zealand (+64)

Nicaragua (+505)

Niger (+227)

Nigeria (+234)

Niue (+683)

Norfolk Islands (+672)

Northern Marianas (+670)

Norway (+47)

Oman (+968)

Palau (+680)

Panama (+507)

Papua New Guinea (+675)

Paraguay (+595)

Peru (+51)

Philippines (+63)

Poland (+48)

Portugal (+351)

Puerto Rico (+1787)

Qatar (+974)

Reunion (+262)

Romania (+40)

Russia (+7)

Rwanda (+250)

San Marino (+378)

Sao Tome & Principe (+239)

Saudi Arabia (+966)

Senegal (+221)

Serbia (+381)

Seychelles (+248)

Sierra Leone (+232)

Singapore (+65)

Slovak Republic (+421)

Slovenia (+386)

Solomon Islands (+677)

Somalia (+252)

South Africa (+27)

Spain (+34)

Sri Lanka (+94)

St. Helena (+290)

St. Kitts (+1869)

St. Lucia (+1758)

Sudan (+249)

Suriname (+597)

Swaziland (+268)

Sweden (+46)

Switzerland (+41)

Syria (+963)

Taiwan (+886)

Tajikstan (+7)

Thailand (+66)

Togo (+228)

Tonga (+676)

Trinidad & Tobago (+1868)

Tunisia (+216)

Turkey (+90)

Turkmenistan (+7)

Turkmenistan (+993)

Turks & Caicos Islands (+1649)

Tuvalu (+688)

Uganda (+256)

UK (+44) -->

Ukraine (+380)

United Arab Emirates (+971)

Uruguay (+598)

USA (+1) -->

Uzbekistan (+7)

Vanuatu (+678)

Vatican City (+379)

Venezuela (+58)

Vietnam (+84)

Virgin Islands - British (+1284)

Virgin Islands - US (+1340)

Wallis & Futuna (+681)

Yemen (North)(+969)

Yemen (South)(+967)

Zambia (+260)

Zimbabwe (+263)

Country *

USA

Afghanistan

Åland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua and Barbuda

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bonaire, Sint Eustatius and Saba

Bosnia and Herzegovina

Botswana

Bouvet Island

Brazil

British Indian Ocean Territory

Brunei Darussalam

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Cayman Islands

Central African Republic

Chad

Chile

China

Christmas Island

Cocos Islands

Colombia

Comoros

Congo

Democratic Republic of

the Congo

Cook Islands

Costa Rica

Côte d"Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

France

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Heard Island and McDonald Islands

Holy See

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Isle of Man

Israel

Italy

Jamaica

Japan

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

North Korea

South Korea

Kuwait

Kyrgyzstan

Lao

Latvia

Lebanon

Lesotho

Liberia

Libyan Arab Jamahiriya

Liechtenstein

Lithuania

Luxembourg

Macao

Macedonia, The Former

Macaolav Republic of

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Netherlands

New Caledonia

New Zealand

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territory

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Russian Federation

Rwanda

Saint Helena, Ascension and Tristan da Cunha

Saint Kitts and Nevis

Saint Lucia

Saint Pierre and Miquelon

Saint Vincent and The Grenadines

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia and The South

Sandwich Islands

Spain

Sri Lanka

Sudan

Suriname

Svalbard and Jan Mayen

Swaziland

Sweden

Switzerland

Syrian Arab Republic

Taiwan

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad and Tobago

Tunisia

Turkey

Turkmenistan

Turks and Caicos Islands

Tuvalu

Uganda

Ukraine

United Arab Emirates

US Minor Outlying Islands

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

British Virgin Islands

US Virgin Islands

Wallis and Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

Kosovo

-->

-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you.You will receive an email shortly. Please check for download the Report.

Related Company ProfilesGrifols SAEthicon US LLCJohnson & JohnsonBiotest AGView all

In an exclusive interview with Pharmaceutical Technology, Schüttrumpf outlined the plasma derived-medicines company’s 2024 goals for its late-stage candidates as several trials come to a head. The aforementioned Preciosa trial (NCT03451292) studying human albumin is focused on patients awaiting a suitable transplant.

Grifols also plans to release data from its Phase III ESsCAPE study (NCT05722938), investigating trimodulin, triple action immunoglobulin with IgM, IgA and IgG, at some point this year.

In February, the company reportPharmaceutical Technologylts from a trial investigating Grifols’ fibrinogen concentrate (FC), BT524, for the treatment of acquired fibrinogen deficiency (AFD). The company now plans to complete European Medicines Agency (EMA) and US Food and Drug Administration (FDA) regulatory submissions, in pursuit of approval. “We are working with different partners. In the immunology, and pulmonary disease space, to support their growth,” says Schüttrumpf.

Grifolsnally, the Spain-headquartered company is exploring partnerships similar to the one it hastrimodulincon, says Schüttrumpf. Grifols began its collaboration with Ethicon, a subsidiary of Johnson & Johnson, in 2017, wherein Grifols agreed to exclusively manufacture and supply plasma-derived products for use in the biosurgery field for 10 years.

See Also:Pelage secures funds to develop regenerative medicine for hair lossGrifols BT524 acquired fibrinogen deficiency (AFD)European Medicines Agency (EMA)US Food and Drug Administration (FDA)pulmonary disease

Praxis Precision Medicines sees highest patent filings and grants during November in Q4 2023Ethicon Grifols Ethicon Johnson & Johnson Grifols

In 2021, Pelages announced the acquisition of Tiancheng (Germany) Phair lossical Holdings, which owned 89.88% of another plasma products specialist Biotest. Grifols is developing trimodulin and B524 with Biotest. Before the acquisition, Grifols had already explored fibrinogen concentrate for the development of Vistaseal (fibrinogen (human) + thrombin (human), commercialised as Veraseal in Europe.

Schüttrumpf highlights Grifol’s ability to complete in-house manufacturing for plasma-derived therapeutics like BT524. He said that this gave the company a major advantage in its operations, also allowing it to offer its manufacturing services to other pharmaceutical companies.

Praxis Precision Medicinesse its 2023 annual financial report on 29 February.

Free ReportHow is the Biopharmaceutical industry evolving?

2021 was Grifolsof continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesBiotestldGrifols Grifolst’s time to lootrimodulinways to create Biotestprepare for the future, anGrifols Grifolsn competitive in the ever-changing landscape.Vistaseal Veraseal

GlobalData’s expansive Grifol examines the business environment and trends that shape the Biopharmaceutical induBT524 We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Grifols Grifolsthe report to: